CEL-SCI Corporation (CVM): Rasio rega marang pendapatan
CEL-SCI Corporation's critical dependence on external manufacturing and testing contractors defines its operational risk. The GURU.Markets portal features a P/S ratio chart, where represents the latest metric reading. CEL-SCI Corporation is developing the Multikine system for the preliminary stimulation of patient immunity. Meanwhile, the business's environmental profile is limited to standard bio-waste disposal in accordance with government regulations.
Rincian analitis perusahaan CEL-SCI Corporation (CVM)
- kuotasi saiki lan rata-rata prakiraan nilai:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- rincian struktur utang lan likuiditas bisnis:
Rasio Total Utang marang Ekuitas CEL-SCI Corporation|CVM - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal cel-sci.com|CVM - Gunggung utang perusahaan|Rasio utang marang aset resik CEL-SCI Corp|CVM - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan CEL-SCI|Likuiditas darurat cel-sci.com
- rincian bathi lan kelipatan pasar:
CVM - Bathi resik perusahaan|Penghasilan resik sing dikarepake CEL-SCI Corporation|CVM - Rasio rega marang bathi|Rasio rega marang bathi sing dikarepake cel-sci.com|CVM - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan CEL-SCI Corp|CVM - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku CEL-SCI|CVM - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan cel-sci.com|CVM - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep CEL-SCI Corporation
- data total pendapatan lan volume dodolan:
Ringkesan analitik perusahaan:CEL-SCI Corp., CVM
The P/S ratio is calculated as the ratio of CEL-SCI Corporation (CVM) market capitalization to its total annual revenue. This metric determines how much investors are willing to pay for every dollar of sales, assessing the efficiency of asset monetization. For the biotechnology sector, characterized by volatile income and a dependence on grants, this indicator becomes a key marker of speculative expectations. Analyzing the price-to-sales ratio helps identify critical points of business overvaluation.
Perusahaan pesaing
ONC - Rega marang dodolan|Rasio rega marang pendapatan Halozyme HALO|Revolution Medicines Inc - Rasio rega marang pendapatan|AAPG: Kapitalisasi marang pendapatan|Multiplikator rega marang pendapatan CG Oncology Therapeutics (CGON)|UroGen Pharma Ltd. (URGN) - Rasio rega marang pendapatan|BCAX - Koefisien rega marang pendapatan|PSNL (Personalis) - Multiplikator P/S|Kapitalisasi marang pendapatan Erasca Inc (ERAS)|Multiplikator P/S DCTH|Koefisien rega marang pendapatan Y-mAbs Corp|Aura Biosciences, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CADL|Accuray - Multiplikator P/S|SELLAS Life Sciences (SLS) - Kapitalisasi marang pendapatan|Actuate Therapeutics, Inc (ACTU) - Rasio rega marang pendapatan|Rega marang dodolan Citius Oncology Inc (CTOR)|Rasio rega marang pendapatan TuHURA Biosciences Inc.|TARA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Fate Therapeutics (FATE)|WHWK: Rasio rega marang dodolan|Rasio rega marang pendapatan TScan Therapeutics, Inc. TCRX|Champions Oncology Inc (CSBR) - Rega marang dodolan|XBIT - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan OSTX (ostherapies.com)|RADX: Multiplikator P/S|Artiva Biotherapeutics (ARTV) - Multiplikator P/S|Kapitalisasi marang pendapatan ANL|VERU (Veru Corporation) - Kapitalisasi marang volume dodolan|Multiplikator P/S TPST|Koefisien rega marang pendapatan xiliotx.com|Rasio rega marang pendapatan Renovaro RENB|Mural Oncology PLC (MURA) - Rega marang dodolan|KAPA - Rasio rega marang pendapatan|OKUR (OnKure Therapeutics Inc) - Rasio kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Kapitalisasi marang pendapatan Curis|Kapitalisasi marang pendapatan APLM|Rasio rega marang pendapatan THAR|Rasio rega marang pendapatan Advanced Biomed Inc (ADVB)|Kapitalisasi marang pendapatan Genprex Inc GNPX|Multiplikator P/S CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Kapitalisasi marang pendapatan|Xenetic Bio - Multiplikator P/S|SLRX - Multiplikator P/S|Purple Biotech Corp (PPBT) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan AONC|BGNE (BeiGene, Ltd.) - Multiplikator P/S|Kapitalisasi marang pendapatan checkpointtx.com (CKPT)|Multiplikator P/S ELEV|ICAD - Rega marang dodolan|Rasio rega marang pendapatan Ikena Oncology IKNA|Rasio kapitalisasi pasar marang pendapatan NTBL|VIRX: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MOR (morphosys.com)|NAYA: Multiplikator P/S|Kapitalisasi marang pendapatan Ascentage Pharma Group International
